Author:
Freedman Mark S.,Coyle Patricia K.,Hellwig Kerstin,Singer Barry,Wynn Daniel,Weinstock-Guttman Bianca,Markovic-Plese Silva,Galazka Andrew,Dangond Fernando,Korich Julie,Reder Anthony T.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference170 articles.
1. Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928.
2. Manfredonia F, Pasquali L, Dardano A, Iudice A, Murri L, Monzani F. Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2008;4(2):321–36.
3. Reder AT, Feng X. How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res. 2014;34(8):589–99.
4. Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78–88.
5. Multiple Sclerosis Society of America. History of multiple sclerosis: mymsaa.org; [updated February 26, 2020]. https://mymsaa.org/ms-information/overview/history/. Accessed Nov 30, 2021.